Skip to main content

The new standard in heart failure management

Non-invasive and scalable intracardiac pressure monitoring

Submit email to get updates

    Acorai has developed a handheld device for non-invasive and scalable intracardiac pressure monitoring, improving quality of care and patient outcomes at a fraction of the current costs in the heart failure workflow

    Four sensor technologies

    Acorai’s SAVE Sensor System ™ is a unique, proprietary hardware architecture combining visual, seismic, acoustic, and electrocardiographic sensors

    Machine Learning

    Acorai’s machine learning engine leverages insights into pressure & flow dynamics in seismic, acoustic and waveform data

    Strong IP portfolio

    3 granted and 3 pending patent families, largest proprietary datasets of its kind and strong IP strategy

    Current standard of care is insufficient

    Today the most accurate monitoring method for heart failure is a right heart catheterization. This is an invasive procedure performed by a cardiologist or pulmonologist with a team, room, and specialized equipment. A long catheter is inserted from an incision and guided to the heart and pulmonary arteries and measurements are taken throughout the process.

    It is a common procedure, but expensive and resource-intensive with unnecessary discomfort for the already fragile heart patient.

    Improved workflow with Acorai

    In the future, Acorai will be the non-invasive, equally accurate, alternative to the right heart catheterization.

    The patient won’t need to suffer an invasive procedure and measurements can be taken more frequently. Measuring with Acorai does not require a specialist team, room and other equipment. The device is simply held onto the patient’s chest for a few minutes after which the result is displayed.

    Acorai can improve workflow efficiencies and reduce costs while decreasing mortality rates and offering a better experience for the affected patient.

    Blog & News

    Stay up-to-date with our progress and news from the industry

    MonitoringRedefining Heart FailureResearchStudies

    Understanding the impact of the STRONG-HF trial

    The New Duo in Heart Failure Management? Niklas Lidströmer Karolinska Institutet, MD, MSc, specialist physician, postgraduate researcher in AI in medicine, senior advisor in AI and medical investments, former AI entrepreneur and founder of an AI-powered medical platform, former head of Medical AI at a variety of med-tech companies, and also previous co-leader of a handful of successful medical start-ups. Currently…
    Matthew Mace
    November 22, 2022
    Industry newsNew age of MedTechResearch

    Navigating the New Age of MedTech Sales & Marketing Series: Healthcare Equity

    This blog shares the combined sales and marketing experience of the Acorai team, and it will discuss what we have learned in an ever-changing MedTech and Life science industry. It aims to give other startups and established leaders insights into how the sector has changed and discuss critical themes and activities that will lead to continued product success.   If you…
    Matthew Mace
    October 9, 2022

    On a mission

    Existing heart failure treatment is invasive, time-consuming and costly, so in 2019 we founded Acorai and set out to develop the first scalable and non-invasive intracardiac pressure monitor in the world.

    Can we leverage a novel combination of non-invasive sensor technologies with state-of-the-art machine learning methods to accurately detect impending heart failure? The interim analysis after 200+ patients in our pilot study with two of Europe’s leading heart failure hospitals shows promising results.

    We believe that it has the potential to dramatically improve the health outcome for more than 60 million people suffering from heart failure around the world.

    Submit your email to follow our journey

      Support and funding